BEST of ASCO Portugal 2024 - ARM

The American Society of Clinical Oncology (ASCO) 2024 Annual Meeting highlighted several developments in supportive care, emphasizing innovative approaches to enhance care through novel interventions and personalized symptom management. This narrative review synthesizes and critically evaluates four of the main studies in supportive care presented: “REACH PC Trial: Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer” by Greer J, et al; “MENAC Trial: Results from a randomized, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy” by Solheim T, et al; “MC2 Trial: A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care” by Hardy J, et al; and “Alliance A222001 Trial: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy” by Stish B, et al. The aim is to provide a comprehensive overview of studies that address symptom management and quality of life (QoL), while emphasizing the clinical implications of the results presented.